Dr. Ryan E. Hall, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,431
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Arkansas College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AR license E-9634 -
Medical Oncology Physician
AR license E-9634
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center-Little Rock Little Rock, AR
- Baptist Health Medical Center North Little Rock North Little Rock, AR
- Conway Regional Medical Center, Inc Conway, AR
- Baptist Health Medical Center-Stuttgart Stuttgart, AR
Medical groups
- Central Arkansas Radiation Therapy Institute Inc (90 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,431
- Services billed
- 379,557
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 37,020 | 25 |
| Injection, pembrolizumab, 1 mg | 33,200 | 50 |
| Injection, oxaliplatin, 0.5 mg | 21,500 | 31 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19,380 | 21 |
| Injection, fosaprepitant, 1 mg | 16,800 | 51 |
| Injection, denosumab, 1 mg | 13,680 | 66 |
| Injection, aprepitant, 1 mg | 11,830 | 34 |
| Injection, paclitaxel protein-bound particles, 1 mg | 11,200 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 10,560 | 229 |
| Injection, azacitidine, 1 mg | 8,500 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Little Rock, AR | 253 |
| Levothyroxine Sodium Other prescribers in Little Rock, AR | 175 |
| Ondansetron Odt (ondansetron) Other prescribers in Little Rock, AR | 171 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Little Rock, AR | 165 |
| Prochlorperazine Maleate Other prescribers in Little Rock, AR | 137 |
| Jakafi (ruxolitinib phosphate) | 114 |
| Anastrozole Other prescribers in Little Rock, AR | 97 |
| Eliquis (apixaban) Other prescribers in Little Rock, AR | 96 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Little Rock, AR | 95 |
| Montelukast Sodium Other prescribers in Little Rock, AR | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $88.44 in total to this clinician.
| Caris Mpi, Inc. | $29.22 |
|---|---|
| Genzyme Corporation | $20.86 |
| Gilead Sciences, Inc. | $19.22 |
| Azurity Pharmaceuticals, Inc. | $19.14 |
| Food and Beverage | $88.44 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $741,879 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non…
Merck Sharp & Dohme LLC - Caris Biorepository Research Protocol
Caris Mpi, Inc. · Recruiting · NCT01499394 - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Inelig…
Merck Sharp & Dohme LLC - A phase 2 randomized doubleblind placebocontrolled study to investigate the efficacy safety and tolerability of ponsegromab in patients with cancer cachexia and elevated concentrations of GDF15 followed by an optional…
Pfizer Inc. - A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.